Epstein-Barr virus latent infection membrane protein increases vimentin expression in human B-cell lines

Latent Epstein-Barr virus (EBV) infection activates B-lymphocyte proliferation through mechanisms which are partially known. One approach to further delineate these mechanisms is to identify cellular genes whose expression is augmented in cells latently infected with EBV. Since EBV-negative Burkitt's lymphoma cells can be grown in continuous culture and EBV can establish growth-altering latent infection in these cells, some effects of EBV on B-lymphocyte gene expression can be studied by using this in vitro system. Pursuing this latter approach, we have used cDNA cloning and subtractive hybridization to identify a gene whose expression is increased after EBV infection. This gene encodes the cytoskeletal protein vimentin. Latent infection of established EBV-negative Burkitt's lymphoma cell lines with the transforming EBV strain, B95-8, resulted in dramatic increases in vimentin mRNA and protein levels, while infection with the nontransforming P3HR1 strain failed to do so. Vimentin induction was reproduced by the expression of the single EBV gene which encodes the latent infection membrane protein (LMP). An amino-terminal LMP deletion mutant did not induce vimentin. These results are of particular interest in light of the transforming potential of LMP, as demonstrated in rodent fibroblasts, and the interaction between vimentin and LMP observed in immunofluorescent colocalization and cell fractionation studies.

[1]  E. Kieff,et al.  Epstein-Barr virus latent membrane protein: induction of B-cell activation antigens and membrane patch formation does not require vimentin , 1989, Journal of virology.

[2]  R. Noelle,et al.  Membrane Ig-cytoskeletal interactions. I. Flow cytofluorometric and biochemical analysis of membrane IgM-cytoskeletal interactions. , 1988, Journal of immunology.

[3]  E. Kieff,et al.  Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity , 1988, Journal of virology.

[4]  E. Kieff,et al.  The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts , 1988, Journal of virology.

[5]  V. Baichwal,et al.  Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. , 1988, Oncogene.

[6]  P. Möller,et al.  Lack of vimentin occurring during the intrafollicular stages of B cell development characterizes follicular center cell lymphomas. , 1988, Blood.

[7]  C. Tseng,et al.  Identification of a novel human B cell activation antigen involved in B cell growth factor-dependent proliferation. , 1988, Journal of immunology.

[8]  G. Lenoir,et al.  Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains , 1988, Journal of virology.

[9]  J. Banchereau,et al.  Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[10]  E. Kieff,et al.  An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes , 1987, Molecular and cellular biology.

[11]  G. Blobel,et al.  Lamin B constitutes an intermediate filament attachment site at the nuclear envelope , 1987, The Journal of cell biology.

[12]  G. Blobel,et al.  Two distinct attachment sites for vimentin along the plasma membrane and the nuclear envelope in avian erythrocytes: a basis for a vectorial assembly of intermediate filaments , 1987, The Journal of cell biology.

[13]  K. Welte,et al.  Purification and biochemical characterization of a human autocrine growth factor produced by Epstein-Barr virus-transformed B cells. , 1987, Journal of immunology.

[14]  E. Kieff,et al.  Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[15]  L. Kaczmarek,et al.  Coding sequence and growth regulation of the human vimentin gene , 1986, Molecular and cellular biology.

[16]  T. Suzuki,et al.  Identification of an early activation antigen (Bac-1) on human B cells. , 1986, Journal of immunology.

[17]  E. Kieff,et al.  Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Hardy,et al.  Expression and function of an early activation marker restricted to human B cells. , 1986, Journal of immunology.

[19]  E. Kieff,et al.  Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus , 1986, Journal of virology.

[20]  E. Kieff,et al.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells , 1985, Cell.

[21]  S. Ferrari,et al.  The effect of cycloheximide on the expression of cell cycle dependent genes. , 1985, Biochemical and biophysical research communications.

[22]  L. Kaczmarek,et al.  Expression of cell-cycle-dependent genes in phytohemagglutinin-stimulated human lymphocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[23]  V. Marchesi,et al.  Site specificity in vimentin-membrane interactions: intermediate filament subunits associate with the plasma membrane via their head domains , 1985, The Journal of cell biology.

[24]  V. Marchesi,et al.  The binding of vimentin to human erythrocyte membranes: a model system for the study of intermediate filament-membrane interactions , 1985, The Journal of cell biology.

[25]  P. Traub Intermediate Filaments: A Review , 1985 .

[26]  R. Schooley,et al.  BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. , 1985, Journal of immunology.

[27]  A. Freedman,et al.  B5, a new B cell-restricted activation antigen. , 1985, Journal of immunology.

[28]  B. Barrell,et al.  Two related but differentially expressed potential membrane proteins encoded by the EcoRI Dhet region of Epstein-Barr virus B95-8 , 1985, Journal of virology.

[29]  R. Baserga,et al.  Cell-cycle-specific cDNAs from mammalian cells temperature sensitive for growth. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[30]  E. Kieff,et al.  Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein , 1984, Journal of virology.

[31]  J. Gordon,et al.  Immortalized B lymphocytes produce B-cell growth factor , 1984, Nature.

[32]  P. Åman,et al.  Soluble factor requirements for the autostimulatory growth of B lymphoblasts immortalized by Epstein-Barr virus , 1984, The Journal of experimental medicine.

[33]  P. Leder,et al.  Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor , 1983, Cell.

[34]  M. Strome,et al.  Self-stimulating growth factor production by B-cell lines derived from Burkitt's lymphomas and other lines transformed in vitro by Epstein-Barr virus. , 1983, Cancer research.

[35]  W. Vainchenker,et al.  Alteration of vimentin intermediate filament expression during differentiation of human hemopoietic cells. , 1983, The EMBO journal.

[36]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[37]  Brent H. Cochran,et al.  Molecular cloning of gene sequences regulated by platelet-derived growth factor , 1983, Cell.

[38]  R. Schooley,et al.  Epstein-Barr virus superinduces a new human b cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts , 1982, Cell.

[39]  K. Dellagi,et al.  Redistribution of intermediate filaments during capping of lymphocyte surface molecules , 1982, Nature.

[40]  M. Epstein,et al.  Monoclonal antibodies to epstein‐barr virus‐induced, transformation‐associated cell surface antigens: Binding patterns and effect upon virus‐specific t‐cell cytotoxicity , 1982, International journal of cancer.

[41]  E. Unanue,et al.  Ligand-induced association of surface immunoglobulin with the detergent-insoluble cytoskeletal matrix of the B lymphocyte. , 1982, Journal of immunology.

[42]  T. Yokochi,et al.  B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. , 1982, Journal of immunology.

[43]  B. Sugden,et al.  Identification of antigenic determinants unique to the surfaces of cells transformed by Epstein–Barr virus , 1981, Nature.

[44]  J. Shelhamer,et al.  Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. , 1981, Journal of immunology.

[45]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[46]  E. Kieff,et al.  Epstein-Barr Virus-Specific RNA III. Mapping of DNA Encoding Viral RNA in Restringent Infection , 1979, Journal of virology.

[47]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[48]  T. Lindahl,et al.  Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line. , 1976, Journal of molecular biology.

[49]  J. Robinson,et al.  Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. H. Pope,et al.  Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes‐like virus , 1968 .

[51]  M. Rowe,et al.  Ligation of the CD23, p45 (BLAST‐2, EBVCS) antigen triggers the cell‐cycle progression of activated B lymphocytes , 1986, European journal of immunology.

[52]  G. Klein,et al.  Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma. , 1982, Advances in cancer research.

[53]  G. Klein The Epstein-Barr virus and human malignancies. , 1976, Advances in pathobiology.

[54]  Ri-chi,et al.  Purification of Biologically Active Globin Messenger RNA by Chromatography on Oligothymidylic acid-Cellulose , 2022 .